TrialPath
Recruiting

A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

NCT06694935 · 1Globe Health Institute
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1b Study of QX1206 in Type 2 Diabetes Mellitus (T2DM) Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
About this study
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.
Eligibility criteria
Inclusion Criteria: * Signed written informed consent must be obtained and documented * 18 years of age and \< 65 years old * BMI ≥ 18 kg/m\^2 and \< 45 kg/m\^2 * T2DM diagnosed per 2021 American Diabetes Association criteria * Diagnosis of NAFLD * For male or female patients of child producing potential: must agree to use contraception or take measures to avoid pregnancy during the study * Women of child-bearing potential (WOCBP) must have a negative pregnancy test * Serum creatinine \< 1.5×ULN or creatinine clearance ≥ 60 ml/min * Participating patients must be able to comply with all study requirements and the study center must have appropriate means of ensuring protocol compliance for each participating patient Exclusion Criteria: * Uncontrolled diabetes * Patients with an active, serious medical disease that limit activities of daily living * Patients with current, significant alcohol consumption or a history of significant alcohol consumption * Patients with any of the following clinical laboratory abnormalities at screen and confirmed by a single repeat if deemed necessary: * Fasting triglycerides \> 500 mg/dL * Fasting direct LDL-C \> 190 mg/dL * AST \> 5.0 × upper limit of normal (ULN) * ALT \> 5.0 × ULN * Alkaline phosphatase (ALP) ≥ 2 × ULN * HbA1c \> 10.5% * Fasting plasma glucose (FPG) \> 240 mg/dL (13.3 mmol/L) * Platelets count \< 140,000/mm\^3 * Patient takes drugs historically associated with NAFLD and other known hepatotoxins * Treatment with drugs (e.g., vitamin E \> 400 IU/day) or herbal supplements with potential anti-NAFLD effect
Study design
Enrollment target: 52 participants
Allocation: na
Masking: none
Age groups: adult
Timeline
Starts: 2025-01-06
Estimated completion: 2025-12
Last updated: 2025-01-13
Interventions
Drug: QX1206
Primary outcomes
  • • Recommended Phase 2 Dose (RP2D) (Baseline Day 1 up to Week 12)
Sponsor
1Globe Health Institute · industry
Contacts & investigators
Contact1Globe Health Institute · contact · T2DM-QX1206-1_Study@1globe-usa.com · 617-649-1157
InvestigatorAndrew Keates, PhD · study_director, 1Globe Health Institute
All locations (1)
Centricity Research Toronto LMC.Recruiting
Toronto, Canada
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD · TrialPath